公开(公告)号：US20060217282A1

公开(公告)日：2006-09-28

申请号：US10532265

申请日：2003-10-29

申请人： Graham Jackson ,  John Collinge ,  Anthony Clarke

发明人： Graham Jackson ,  John Collinge ,  Anthony Clarke

IPC分类号： C11D3/386

CPC分类号： C11D3/48 ,  A61B90/70 ,  A61L2/07 ,  A61L2/16 ,  A61L2/18 ,  C11D3/386

摘要： The present invention relates to methods for prion decontamination comprising (i) contacting an entity to be decontaminated with a detergent, (ii) contacting said entity with one or more protease(s), and optionally (iii) autoclaving said entity. The invention further relates to kits comprising detergents and proteases for prion decontamination, and compositions comprising detergents and proteases for prion decontamination.

摘要翻译： 本发明涉及用于朊病毒去污的方法，其包括（i）使待去污染的实体与洗涤剂接触，（ii）使所述实体与一种或多种蛋白酶接触，和任选地（iii）高压灭菌所述实体。 本发明还涉及包含用于朊病毒去污的洗涤剂和蛋白酶的试剂盒，以及包含洗涤剂和蛋白酶用于朊病毒去污的组合物。

公开(公告)号：US20060029547A1

公开(公告)日：2006-02-09

申请号：US11140416

申请日：2005-05-27

申请人： John Collinge ,  Anthony Clarke ,  Graham Jackson

发明人： John Collinge ,  Anthony Clarke ,  Graham Jackson

IPC分类号： A61K49/00 ,  C12P21/06 ,  C07K14/47

CPC分类号： A61K49/0058 ,  A61K38/00 ,  A61K51/1018 ,  C07K14/47 ,  C07K16/2872

摘要： The present invention relates to a method of making a β-form of a prion protein which preferably has more β-sheet than α-helix structure and is soluble in the absence of a denaturant and/or is non-aggregated and exhibits partial resistance to digestion with proteinase K. The invention also relates to use of the β-form in medicine, especially for raising to antibodies useful in the treatment and/or diagnosis of prion diseases. The invention also relates to methods of screening for compounds which are capable of inhibiting and/or reversing the conversion of the native α-form of a prion protein to a β-form, and to uses of identified compounds in medicine.

摘要翻译： 本发明涉及一种制备朊蛋白的β型的方法，其优选比α-螺旋结构具有更多的β-折叠，并且在不存在变性剂和/或非聚集的情况下是可溶的，并表现出对 用蛋白酶K消化。本发明还涉及β-形式在药物中的用途，特别是用于提供可用于治疗和/或诊断朊病毒疾病的抗体。 本发明还涉及筛选能够抑制和/或逆转天然α-形式的朊病毒蛋白转化为β型的化合物的方法，以及在药物中使用鉴定的化合物。

公开(公告)号：US20080187573A1

公开(公告)日：2008-08-07

申请号：US11850141

申请日：2007-09-05

申请人： Francesca Mary Brewer ,  Edward Stuart Johnson ,  Anthony Clarke

发明人： Francesca Mary Brewer ,  Edward Stuart Johnson ,  Anthony Clarke

IPC分类号： A61K31/131 ,  A61K9/00

CPC分类号： A61K31/137 ,  A61K9/0056 ,  A61K9/2095 ,  A61K31/136

摘要： A fast dispersing solid pharmaceutical composition having a monoamine oxidase B inhibitor as the only active ingredient is disclosed for the treatment of Parkinson's disease. The composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membranes, such that at least 5% of the active ingredient is absorbed in one minute, as determined by a buccal absorption test.

摘要翻译： 公开了具有单胺氧化酶B抑制剂作为唯一活性成分的快速分散固体药物组合物用于治疗帕金森病。 将组合物配制成促进通过颊，舌下，咽和/或食管粘膜的吸收，使得至少5％的活性成分在一分钟内被吸收，如通过口腔吸收试验测定的。

公开(公告)号：US06316027B1

公开(公告)日：2001-11-13

申请号：US09666173

申请日：2000-09-21

申请人： Edward Stewart Johnson ,  Anthony Clarke ,  Richard D. Green

发明人： Edward Stewart Johnson ,  Anthony Clarke ,  Richard D. Green

IPC分类号： A61K920

CPC分类号： A61K9/2095 ,  A61K9/0056 ,  A61K31/485

摘要： In one embodiment, this invention relates to a pharmaceutical composition for oral administration consisting essentially of a gelatin at a concentration up to 5% by weight as a carrier, a solvent, and, as an active ingredient, a dopamine agonist. Alternatively, the invention relates to a composition that takes the form of a solid, unitary fast-dispersing dosage form comprised of a network of an active ingredient after and a water-soluble or water dispersible matrix forming agent or carrier which is inert towards the active ingredient after subliming solvent from the composition in the solid state. The dosage is designed to completely disintegrate within 1 to 30 seconds of being placed in the oral cavity. Compositions which further comprise an anti-emetic and/or an opioid antagonist are also provided herein.

摘要翻译： 在一个实施方案中，本发明涉及用于口服给药的药物组合物，其基本上由作为载体的浓度高达5重量％的明胶，溶剂和作为活性成分的多巴胺激动剂组成。 或者，本发明涉及一种组合物，其采取由活性成分的网络组成的固体，单一快速分散剂型和对活性成分为惰性的水溶性或水分散性基质形成剂或载体的形式 在固体状态下从组合物中升华溶剂后的成分。 该剂量被设计为在放置在口腔中的1至30秒内完全分解。 还提供还包含抗呕吐和/或阿片样物质拮抗剂的组合物。

公开(公告)号：US09820937B2

公开(公告)日：2017-11-21

申请号：US12782584

申请日：2010-05-18

申请人： Francesca Mary Brewer ,  Edward Stewart Johnson ,  Anthony Clarke

发明人： Francesca Mary Brewer ,  Edward Stewart Johnson ,  Anthony Clarke

IPC分类号： A61K31/137 ,  A61K9/20 ,  A61K9/00 ,  A61K31/136

CPC分类号： A61K9/0056 ,  A61K9/2095 ,  A61K31/136 ,  A61K31/137

摘要： The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analog can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.

公开(公告)号：US08152593B2

公开(公告)日：2012-04-10

申请号：US12458023

申请日：2009-06-29

申请人： Carol Barton ,  Anthony Clarke

发明人： Carol Barton ,  Anthony Clarke

IPC分类号： A41C3/00

CPC分类号： A41C3/065

摘要： An open front undergarment having a form that allows the back of the garment to be closed and the front of the garment to be completely open and free from clasps, fabric or fasteners in the front between the cups. The open front undergarment includes a brassiere having an underwire and an overwire to form a frame, a rear band, a pair of cups extending from opposite ends of the rear band a cover material and a slip-resistant band. The underwire runs through the lower perimeter of a lower portion of the brassiere and the overwire runs through the upper perimeter. The underwire and overwire can be formed of a metal or a metal coated with plastic. The frame can also be formed of a single ductile member. The brassiere also includes a flexure region at the rear band to allow for flexure of the back and torso of the wearer.

摘要翻译： 具有允许衣服的背部被封闭并且衣服的前部完全打开并且没有在杯之间的前部的扣子，织物或紧固件的形式的敞开的前部内衣。 敞开的前内裤包括一个胸罩，其具有一根线和一根线以形成一个框架，一个后带，一对从背带的两端延伸的覆盖材料和防滑带。 下线穿过胸罩的下部的下周边，并且超线穿过上周边。 线缆和超线缆可以由金属或涂覆有塑料的金属形成。 框架也可以由单个延性构件形成。 胸罩还包括在后带的弯曲区域，以允许穿着者的背部和躯干的挠曲。

公开(公告)号：US20100009598A1

公开(公告)日：2010-01-14

申请号：US12458023

申请日：2009-06-29

申请人： Carol Barton ,  Anthony Clarke

发明人： Carol Barton ,  Anthony Clarke

IPC分类号： A41C3/00 ,  A41C3/10

CPC分类号： A41C3/065

摘要： An open front undergarment having a form that allows the back of the garment to be closed and the front of the garment to be completely open and free from clasps, fabric or fasteners in the front between the cups. The open front undergarment includes a brassiere having an underwire and an overwire to form a frame, a rear band, a pair of cups extending from opposite ends of the rear band a cover material and a slip-resistant band. The underwire runs through the lower perimeter of a lower portion of the brassiere and the overwire runs through the upper perimeter. The underwire and overwire can be formed of a metal or a metal coated with plastic. The frame can also be formed of a single ductile member. The brassiere also includes a flexure region at the rear band to allow for flexure of the back and torso of the wearer.

摘要翻译： 具有允许衣服的背部被封闭并且衣服的前部完全打开并且没有在杯之间的前部的扣子，织物或紧固件的形式的敞开的前部内衣。 敞开的前内裤包括一个胸罩，其具有一根线和一根线以形成一个框架，一个后带，一对从背带的两端延伸的覆盖材料和防滑带。 下线穿过胸罩的下部的下周边，并且超线穿过上周边。 线缆和超线缆可以由金属或涂覆有塑料的金属形成。 框架也可以由单个延性构件形成。 胸罩还包括在后带的弯曲区域，以允许穿着者的背部和躯干的挠曲。

公开(公告)号：US20130131098A1

公开(公告)日：2013-05-23

申请号：US13669148

申请日：2012-11-05

申请人： Anthony Clarke

发明人： Anthony Clarke

IPC分类号： A61K31/435 ,  A61K9/00

CPC分类号： A61K31/435 ,  A61K9/0053 ,  A61K9/006 ,  A61K31/473

摘要： The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function.

摘要翻译： 本发明提供了一种试剂盒，其在容器的分开的隔室中包含以下组分（a）和（b）：（a）阿扑吗啡或其药学上可接受的酸加成盐和药学上可接受的赋形剂或载体的组合; 和（b）包含稀释剂和pH调节剂的溶液; 呈现的组分使得它们可以在使用时被组合成调节至pH范围从轻度酸性至碱性且适合于口腔给药的制剂。 该制剂可用于治疗帕金森病和促进性功能。

公开(公告)号：US20100227933A1

公开(公告)日：2010-09-09

申请号：US12782584

申请日：2010-05-18

申请人： Francesca Mary Brewer ,  Edward Stewart Johnson ,  Anthony Clarke

发明人： Francesca Mary Brewer ,  Edward Stewart Johnson ,  Anthony Clarke

IPC分类号： A61K31/137 ,  A61P25/16 ,  A61P25/28

CPC分类号： A61K9/0056 ,  A61K9/2095 ,  A61K31/136 ,  A61K31/137

摘要： The invention described herein provides a fast dispersing oral solid dosage form containing monoamine oxidase B inhibitor (MAO-B inhibitor) as the active ingredient, and method of treating disease therewith, such as Parkinson's disease. In one embodiment, the monoamine oxidase B inhibitor selegiline or its analogue can be the sole active ingredient in the composition administered. The dosage form composition is formulated to promote absorption through the buccal, sublingual, pharyngeal and/or esophageal mucous membrane tissue, such that at least 5% of the active ingredient is absorbed within one minute of placement in the oral cavity, as determined by a buccal absorption test. Monoamine oxidase B inhibitor compounds administered in accordance with the invention decrease the amount of undesirable metabolites associated with first pass effect of selegiline, for example, such as amphetamine and methamphetamine. The invention provides a number of other advantages over conventional orally administered tablet forms, including administration of monoamine oxidase B inhibitor compounds to patients that have difficulty swallowing.

摘要翻译： 本文描述的本发明提供了含有单胺氧化酶B抑制剂（MAO-B抑制剂）作为活性成分的快速分散口服固体剂型，以及用于治疗疾病如帕金森病的方法。 在一个实施方案中，单胺氧化酶B抑制剂司来吉兰或其类似物可以是所施用组合物中的唯一活性成分。 配制剂型组合物以促进通过颊，舌下，咽和/或食管粘膜组织的吸收，使得至少5％的活性成分在放置在口腔中的一分钟内被吸收，如通过 颊吸收试验。 根据本发明施用的单胺氧化酶B抑制剂化合物减少与司来吉兰（例如苯丙胺和甲基苯丙胺）的首次通过效应相关的不合需要的代谢物的量。 本发明提供了与常规口服给药的片剂形式相比的许多其它优点，包括向吞咽困难的患者施用单胺氧化酶B抑制剂化合物。

公开(公告)号：US20090023766A1

公开(公告)日：2009-01-22

申请号：US11919799

申请日：2006-05-08

申请人： Anthony Clarke

发明人： Anthony Clarke

IPC分类号： A61K31/473 ,  A61P15/10

CPC分类号： A61K31/435 ,  A61K9/0053 ,  A61K9/006 ,  A61K31/473

摘要： The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function.

摘要翻译： 本发明提供了一种试剂盒，其在容器的分开的隔室中包含以下组分（a）和（b）：（a）阿扑吗啡或其药学上可接受的酸加成盐和药学上可接受的赋形剂或载体的组合; 和（b）包含稀释剂和pH调节剂的溶液; 呈现的组分使得它们可以在使用时被组合成调节至pH范围从轻度酸性至碱性且适合于口腔给药的制剂。 该制剂可用于治疗帕金森病和促进性功能。